肿瘤靶向干扰素-α基因治疗胶质母细胞瘤:1期试验
主要终点为输注后90天内安全性和耐受性,未观察到剂量限制性毒性,最高测试剂量为4.0×10^6 CD34+细胞/kg。中位总生存期16.7个月,中位无进展生存期8.1个月。
要点
- Temferon在最高剂量下未观察到剂量限制性毒性,安全性可接受。
- 选择白消安预处理方案用于后续开发。
- 中位总生存期16.7个月,中位无进展生存期8.1个月。
核心结论
- Temferon在新诊断胶质母细胞瘤患者中是一种安全且可耐受的免疫治疗策略。
研究设计与样本
- 测试Temferon剂量范围为0.5×10^6至4.0×10^6 CD34+细胞/kg,共8个队列,预处理方案为BCNU或白消安,联合或不联合塞替派。
- 主要终点为输注后90天内的安全性和耐受性。
主要发现
- 未观察到剂量限制性毒性,最高测试剂量为4.0×10^6 CD34+细胞/kg。
- 选择白消安预处理方案用于进一步开发。
- 不良事件包括实验室异常、血细胞减少和感染,与自体干细胞移植一致。
- 中位总生存期和中位无进展生存期分别为16.7个月和8.1个月(从诊断起算)。
- 多数患者维持良好体能状态和生活质量;基因工程细胞在骨髓和血液中长期检测到,干扰素-α水平极低。
临床怎么用
- Temferon可作为新诊断胶质母细胞瘤患者的一种安全可耐受的免疫治疗策略。
- 白消安预处理方案被选为后续开发方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Glioblastoma (GBM) is an immunologically cold brain tumor with poor outcome, characterized by a myeloid-driven immunosuppressive microenvironment. Here we report an interim analysis of a first-in-human phase 1/2a dose-escalation study evaluating Temferon-a genetically engineered autologous stem cell transplant designed to deliver interferon-α2 by means of myeloid progeny recruited to the GBM TME and locally activate antitumor immunity. Twenty-four newly diagnosed patients with GBM and unmethylated MGMT promoter were treated across eight cohorts following surgical resection and radiotherapy, testing Temferon doses ranging from 0.5 × 106 to 4.0 × 106 CD34+ cells kg-1 and different conditioning regimens (BCNU or busulfan, with or without thiotepa). The primary endpoint was safety and tolerability within 90 days after infusion. Secondary endpoints included long-term safety, dose and conditioning regimen selection, Temferon engraftment, clinical response, quality of life and survival. No dose-limiting toxicities were observed up to the highest dose level of temferon tested. Busulfan conditioning was selected for further development. Adverse events included laboratory abnormalities, cytopenias and infections consistent with autologous stem cell transplant. Median overall survival and progression-free survival were 16.7 months and 8.1 months from diagnosis, respectively, with most patients maintaining good performance status and quality of life. Genetically engineered cells were detected long term in the bone marrow and the blood, where minimal amounts of interferon-α were measured. Temferon is a safe and tolerable immunotherapeutic strategy in patients with newly diagnosed GBM. ClinicalTrials.gov: NCT03866109 .
引用
- Gentner B, Eoli M, Farina F, et al. Tumor-targeted interferon-α gene therapy for glioblastoma: a phase 1 trial. Nat Med. 2026. PMID: 42225991. doi:10.1038/s41591-026-04419-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。